IQVIA (IQV) Revenue & Revenue Breakdown
IQVIA Revenue Highlights
Latest Revenue (Y)
$15.40B
Latest Revenue (Q)
$3.90B
Main Segment (Y)
Research And Development Solutions
Main Geography (Y)
Americas
IQVIA Revenue by Period
IQVIA Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $15.40B | 2.81% |
| 2023-12-31 | $14.98B | 3.98% |
| 2022-12-31 | $14.41B | 3.86% |
| 2021-12-31 | $13.87B | 22.14% |
| 2020-12-31 | $11.36B | 2.44% |
| 2019-12-31 | $11.09B | 6.49% |
| 2018-12-31 | $10.41B | 6.91% |
| 2017-12-31 | $9.74B | 41.60% |
| 2016-12-31 | $6.88B | 19.88% |
| 2015-12-31 | $5.74B | 5.08% |
| 2014-12-31 | $5.46B | 7.07% |
| 2013-12-31 | $5.10B | 4.81% |
| 2012-12-31 | $4.87B | 12.43% |
| 2011-12-31 | $4.33B | 10.29% |
| 2010-12-31 | $3.92B | - |
IQVIA generated $15.40B in revenue during NA 2024, up 2.81% compared to the previous quarter, and up 138.93% compared to the same period a year ago.
IQVIA Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $3.90B | 2.15% |
| 2024-06-30 | $3.81B | 1.98% |
| 2024-03-31 | $3.74B | -4.32% |
| 2023-12-31 | $3.91B | 4.63% |
| 2023-09-30 | $3.74B | 0.21% |
| 2023-06-30 | $3.73B | 2.08% |
| 2023-03-31 | $3.65B | -2.33% |
| 2022-12-31 | $3.74B | 4.97% |
| 2022-09-30 | $3.56B | 0.59% |
| 2022-06-30 | $3.54B | -0.76% |
| 2022-03-31 | $3.57B | -1.87% |
| 2021-12-31 | $3.64B | 7.23% |
| 2021-09-30 | $3.39B | -1.37% |
| 2021-06-30 | $3.44B | 0.85% |
| 2021-03-31 | $3.41B | 3.37% |
| 2020-12-31 | $3.30B | 18.38% |
| 2020-09-30 | $2.79B | 10.51% |
| 2020-06-30 | $2.52B | -8.46% |
| 2020-03-31 | $2.75B | -4.87% |
| 2019-12-31 | $2.90B | 4.55% |
| 2019-09-30 | $2.77B | 1.06% |
| 2019-06-30 | $2.74B | 2.09% |
| 2019-03-31 | $2.68B | -0.15% |
| 2018-12-31 | $2.69B | 3.62% |
| 2018-09-30 | $2.59B | 1.05% |
| 2018-06-30 | $2.57B | 0.16% |
| 2018-03-31 | $2.56B | -0.54% |
| 2017-12-31 | $2.58B | 4.54% |
| 2017-09-30 | $2.46B | 3.79% |
| 2017-06-30 | $2.38B | 2.28% |
| 2017-03-31 | $2.32B | -0.68% |
| 2016-12-31 | $2.34B | 56.16% |
| 2016-09-30 | $1.50B | -3.57% |
| 2016-06-30 | $1.55B | 4.20% |
| 2016-03-31 | $1.49B | -2.08% |
| 2015-12-31 | $1.52B | 6.81% |
| 2015-09-30 | $1.42B | -1.30% |
| 2015-06-30 | $1.44B | 7.12% |
| 2015-03-31 | $1.35B | -4.50% |
| 2014-12-31 | $1.41B | 0.79% |
| 2014-09-30 | $1.40B | 4.40% |
| 2014-06-30 | $1.34B | 2.54% |
| 2014-03-31 | $1.31B | -5.17% |
| 2013-12-31 | $1.38B | 15.33% |
| 2013-09-30 | $1.20B | -7.71% |
| 2013-06-30 | $1.30B | 5.44% |
| 2013-03-31 | $1.23B | -3.89% |
| 2012-12-31 | $1.28B | 6.59% |
| 2012-09-30 | $1.20B | -2.53% |
| 2012-06-30 | $1.23B | 6.41% |
| 2012-03-31 | $1.16B | - |
IQVIA generated $3.90B in revenue during Q3 2024, up 2.15% compared to the previous quarter, and up 104.51% compared to the same period a year ago.
IQVIA Revenue Breakdown
IQVIA Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| Technology And Analytics Solutions | $6.16B | $5.86B | $5.75B | $5.53B | $4.86B |
| Research And Development Solutions | $8.53B | $8.39B | $7.92B | $7.56B | $5.76B |
| Contract Sales And Medical Solutions | $718.00M | $727.00M | $743.00M | $784.00M | $741.00M |
IQVIA's latest annual revenue breakdown by segment (product or service), as of Dec 24: Research And Development Solutions (55.35%), Technology And Analytics Solutions (39.99%), and Contract Sales And Medical Solutions (4.66%).
Quarterly Revenue by Product
| Product/Service | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Technology And Analytics Solutions | $1.66B | $1.55B | $1.50B | $1.45B | $1.53B | $1.43B | $1.46B | $1.44B | $1.50B | $1.40B | $1.41B | $1.44B | $1.50B | $1.34B | $1.35B | $1.35B | $1.43B | $1.21B | $1.11B | $1.12B |
| Research And Development Solutions | $2.12B | $2.16B | $2.15B | $2.10B | $2.15B | $2.12B | $2.10B | $2.03B | $2.06B | $1.98B | $1.95B | $1.93B | $1.94B | $1.85B | $1.89B | $1.87B | $1.68B | $1.40B | $1.24B | $1.44B |
| Contract Sales And Medical Solutions | $177.00M | $180.00M | $172.00M | $189.00M | $186.00M | $183.00M | $176.00M | $182.00M | $182.00M | $183.00M | $183.00M | $195.00M | $196.00M | $201.00M | $194.00M | $193.00M | $189.00M | $179.00M | $177.00M | $196.00M |
IQVIA's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Research And Development Solutions (53.64%), Technology And Analytics Solutions (41.89%), and Contract Sales And Medical Solutions (4.47%).
IQVIA Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 24 | Dec 23 |
|---|---|---|
| EMEA | $4.92B | $4.46B |
| Asia Pacific | $3.13B | $2.97B |
| Americas | $7.36B | $7.55B |
IQVIA's latest annual revenue breakdown by geography, as of Dec 24: Americas (47.75%), EMEA (31.94%), and Asia Pacific (20.31%).
Quarterly Revenue by Country
| Country | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 18 |
|---|---|---|---|---|---|---|---|
| Americas | $1.85B | $1.84B | $1.86B | $1.80B | $5.70B | $1.86B | $1.17B |
| Asia Pacific | $807.00M | $771.00M | $773.00M | $778.00M | $2.18B | $791.00M | $501.00M |
| EMEA | $1.30B | $1.29B | $1.18B | $1.16B | $3.37B | $1.09B | - |
| Europe And Africa | - | - | - | - | - | - | $890.00M |
IQVIA's latest quarterly revenue breakdown by geography, as of Dec 24: Americas (46.82%), EMEA (32.79%), and Asia Pacific (20.39%).
IQVIA Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| IQV | IQVIA | $15.40B | $3.90B |
| LH | Laboratory Corporation of America | $12.16B | $3.35B |
| ICLR | ICON Public | $8.12B | $2.09B |
| CRL | Charles River Laboratories | $4.05B | $1.03B |
| IDXX | IDEXX Laboratories | $3.90B | $975.54M |
| MTD | Mettler-Toledo | $3.87B | $954.53M |
| WAT | Waters | $2.96B | $740.30M |
| RVTY | Revvity | $2.76B | $641.72M |
| MEDP | Medpace | $2.11B | $558.57M |
| QGEN | Qiagen | $1.97B | $458.80M |
| NEOG | Neogen | $924.22M | $220.98M |
| TWST | Twist Bioscience | $312.97M | - |